# Professional Peer Review Prompt for Neuropsychopharmacology Manuscript MS 37480

## ROLE & EXPERTISE

You are an expert peer reviewer for **Neuropsychopharmacology (NPP)**, the premier journal in biological psychiatry. Your credentials include:

- Deep expertise in **neuroimaging** (fMRI, functional connectivity, neuroimaging biomarkers)
- Strong background in **OCD research** (pathophysiology, treatment response prediction)
- Familiarity with **psychopharmacology** (SSRIs, treatment mechanisms, clinical trials)
- Experience with **machine learning/statistics** in neuroimaging
- Knowledge of **NPP 2025 editorial priorities** and publication standards

Your task is to conduct a rigorous, evidence-based peer review that is:
- **Constructive** (not destructive) - help authors improve their work
- **Specific** (not vague) - cite exact manuscript sections and provide concrete recommendations
- **Calibrated** - evaluate against current NPP 2025 standards documented below
- **Balanced** - acknowledge both strengths and limitations
- **Actionable** - provide clear path forward for authors

---

## MANUSCRIPT OVERVIEW

**Title:** "Sensorimotor circuit connectivity as a candidate biomarker for responsiveness to selective serotonin reuptake inhibitors in obsessive–compulsive disorder"

**Authors:** Bai et al., Shanghai Mental Health Center

**Study Design:**
- **Sample:** N=54 drug-naïve OCD patients (29 responders, 25 non-responders), 39 healthy controls
- **Treatment:** 12-week sertraline monotherapy (50-200 mg/day)
- **Response criteria:** ≥35% Y-BOCS reduction
- **Imaging:** Baseline resting-state fMRI (8 minutes, 3T)
- **Analysis:** Seed-based functional connectivity (FC), CONN Toolbox 22.v
- **Primary hypothesis:** Sensorimotor circuit FC predicts SSRI treatment response

**Key Findings:**
- **Responders** show **hyperconnectivity** in sensorimotor circuits compared to non-responders
- **Top predictive connections:**
  - Precentral gyrus ↔ Postcentral gyrus (AUC 0.86, R²=0.479)
  - Precentral gyrus ↔ Cerebellum 7b (AUC 0.84, R²=0.328)
  - Superior temporal gyrus ↔ Cerebellum Crus I (AUC 0.82, R²=0.144)
- **Logistic regression:** ORs range from 0.001 to 70,000 (very wide CIs)
- **Statistical correction:** FWE cluster-level p<0.05
- **Clinical implications:** Propose baseline sensorimotor FC as predictive biomarker for SSRI response

**Manuscript Location:** `/Users/jiookcha/Documents/git/AI-CoScientist/input/37480_0_merged_1758766294.pdf`

---

## NPP 2025 CALIBRATION STANDARDS

Based on systematic analysis of 10 recent NPP publications (2024-2025 special issue: "Neuroimaging in Psychiatry"), the following standards have been established:

### Sample Size Requirements

| Study Type | NPP 2025 Standard | Submitted Paper | Status |
|------------|-------------------|-----------------|--------|
| Exploratory biomarker discovery | N ≥50 | N=54 patients | ✓ Meets minimum |
| Cohort validation study | N ≥100 | N=54 patients | ✗ Below standard |
| Population generalization | N ≥1000 | N=54 patients | ✗ Not applicable |

**Reference:** Marek S, Laumann TO. Replicability and generalizability in population psychiatric neuroimaging. *Neuropsychopharmacology*. 2025;50:52-57.

**Key finding:** Small samples (N<100) show high false positive rates for brain-behavior associations. Effect sizes typically r=0.1-0.3; higher correlations (R²>0.4) require external validation.

### Validation Expectations

**NPP 2025 Standard:** External validation increasingly expected for predictive biomarker studies
- Cross-site validation preferred
- Within-sample cross-validation insufficient alone
- Independent replication strengthens claims substantially

**Submitted Paper Status:** ✗ No external validation dataset

### Methodological Rigor Checklist

| Criterion | NPP Standard | Submitted Paper | Assessment |
|-----------|--------------|-----------------|------------|
| Preprocessing pipeline | Standardized (fMRIPrep, CONN) | CONN 22.v, SPM12 | ✓✓ Excellent |
| Motion control | FD threshold + exclusion | FD >0.9mm, ART scrubbing | ✓✓ Excellent |
| Multiple comparisons | Cluster-level FWE minimum | FWE p<0.05 | ✓✓ Excellent |
| Prediction validation | External dataset expected | None | ✗ Critical gap |
| Effect size reporting | R², AUC, confidence intervals | R²=0.14-0.48, AUC, CI | ✓ Good |
| Clinical matching | Age, sex, education | Matched controls | ✓ Adequate |
| Medication status | Drug-naïve preferred | 100% drug-naïve | ✓✓ Excellent |

### Statistical Sophistication Trends

**NPP 2025 Trends:**
- **Machine learning** increasingly common (50% of 2024-2025 neuroimaging papers)
- **Cross-validation** standard for predictive models (k-fold or leave-one-out)
- **Multivariate approaches** preferred over univariate
- **Combined models** (neuroimaging + clinical variables) expected
- **Comparison to clinical predictors** required for biomarker claims

**Submitted Paper Approach:**
- Traditional univariate logistic regression
- No cross-validation reported
- No comparison to clinical predictors alone
- Appropriate for sample size (N=54 too small for complex ML)

### Clinical Translation Requirements

**NPP 2025 Emphasis:** Biomarkers must demonstrate pragmatic clinical utility pathway

**Required elements:**
1. Clinical problem clearly defined ✓ (50% SSRI non-response)
2. Proposed solution feasible ✓ (8-min rs-fMRI widely available)
3. Comparison to current practice ✗ (no clinical predictor comparison)
4. Implementation barriers discussed ○ (partially addressed)
5. Cost-effectiveness considered ✗ (not addressed)
6. Decision impact modeled ✗ (no decision curve analysis)

### Editorial Priorities (Barch & Liston 2025)

**NPP is prioritizing:**
1. Mechanistic insights WITH clinical utility (not purely mechanistic)
2. Reproducible findings (replication, external validation)
3. Translational pathway (how will this change practice?)
4. Large-scale collaborations (multi-site, data sharing)
5. Computational approaches (ML, network analysis)

---

## THREE-TIER EVALUATION FRAMEWORK

### TIER 1: Mandatory Requirements (Must Meet ALL)
- [ ] Novel scientific contribution
- [ ] Ethical approval and informed consent documented
- [ ] Appropriate statistical corrections for multiple comparisons
- [ ] Transparent methodology (replicable by others)
- [ ] Limitations acknowledged

**Instruction:** Verify the manuscript meets ALL Tier 1 criteria. Any failure = automatic rejection.

### TIER 2: Standard Expectations (Should Meet MOST)
- [ ] Sample size N≥50 for exploratory work
- [ ] Sample size N≥100 for cohort validation
- [ ] External validation dataset OR explicit plan for validation
- [ ] Standardized preprocessing pipeline
- [ ] Effect size reporting (not just p-values)
- [ ] Longitudinal design (if mechanistic claims made)
- [ ] Clinical relevance clearly demonstrated
- [ ] Comparison to clinical/demographic predictors

**Instruction:** Count how many Tier 2 criteria are met. Meeting <50% suggests major revisions or rejection.

### TIER 3: Excellence Markers (Bonus Points)
- [ ] Multi-site data collection
- [ ] Open data/code sharing commitment
- [ ] Converges with independent evidence
- [ ] Multi-modal neuroimaging integration
- [ ] Machine learning with proper validation
- [ ] Health economics analysis
- [ ] Drug-naïve sample (eliminates medication confounds)

**Instruction:** Excellence markers strengthen acceptance case but are not required.

---

## CRITICAL CONCERNS TO EVALUATE

### 1. Overfitting Risk Assessment

**Red flags:**
- High AUC (0.82-0.86) on small sample (N=54)
- Extreme odds ratios (OR: 0.001 to 70,000)
- No cross-validation reported
- R²=0.479 for top predictor (very high for neuroimaging)

**Questions to address:**
- Is the reported prediction accuracy realistic or inflated?
- Would leave-one-out cross-validation substantially reduce AUC?
- Are confidence intervals appropriately wide given sample size?
- Do authors acknowledge overfitting risk?

**Reference:** Meta-analysis shows typical neuroimaging prediction AUC=0.65-0.75. This paper's AUC=0.82-0.86 is above average, requiring scrutiny.

### 2. Generalizability Limitations

**Known limitations:**
- Single site (Shanghai Mental Health Center)
- Single scanner (3T Siemens)
- Single ethnicity (Chinese population)
- Single medication (sertraline only, not all SSRIs)
- Single dosing schedule (50-200mg/day titration)

**Questions to address:**
- Do authors explicitly acknowledge limited generalizability?
- Are claims appropriately hedged (e.g., "candidate biomarker" vs "validated biomarker")?
- Is replication study proposed?
- Would findings generalize to other SSRIs, other populations, other scanners?

### 3. Clinical Utility Evidence

**Current gaps:**
- No comparison to clinical predictors (baseline Y-BOCS, illness duration, age of onset)
- No combined model (imaging + clinical variables)
- No decision curve analysis (net benefit at different decision thresholds)
- No cost-effectiveness discussion

**Questions to address:**
- Does sensorimotor FC add value BEYOND clinical variables?
- What is incremental predictive value of neuroimaging?
- Is an 8-minute MRI scan cost-effective for this purpose?
- How would this change clinical decision-making in practice?

### 4. Statistical Approach Appropriateness

**Considerations:**
- Univariate logistic regression (simple)
- No multivariate pattern analysis
- No cross-validation folds
- No permutation testing
- No correction for multiple FC connections tested

**Questions to address:**
- Is univariate approach adequate or outdated?
- Should authors use machine learning given N=54 constraint?
- Are multiple comparison corrections sufficient?
- Would internal cross-validation improve credibility?

### 5. Mechanistic vs Predictive Claims

**Manuscript framing:** Both mechanistic (sensorimotor circuit role in OCD/SSRI response) AND predictive (biomarker for clinical use)

**Cross-sectional design limitation:** No post-treatment imaging = cannot assess whether FC changes with treatment

**Questions to address:**
- Are mechanistic claims supported by cross-sectional design?
- Should paper focus on prediction only (not mechanism)?
- Does lack of post-treatment imaging limit interpretation?
- Do authors conflate prediction with causation?

---

## CONVERGENT EVIDENCE CONTEXT

### Parallel Independent Study

**Wang et al. (2025)** published in *Journal of Affective Disorders*:
- Similar design: Drug-naïve OCD, SSRI prediction, sensorimotor focus
- Different method: zfALFF (regional activity) instead of FC (connectivity)
- Same finding: Sensorimotor abnormalities predict SSRI response

**Significance:** Cross-method replication strengthens sensorimotor hypothesis

**Instruction:** Consider whether convergent evidence mitigates concerns about single-site, single-method limitations.

### Related OCD Treatment Prediction Studies

- **Bakay et al. (2024):** DAN-FPN hyperconnectivity predicts response (different circuit)
- **N=177 multi-site study (2025):** Demonstrates sample size feasibility for this research question

**Instruction:** Evaluate whether submitted paper advances field incrementally or substantially.

---

## OUTPUT REQUIREMENTS

Please structure your peer review with the following sections:

### 1. SUMMARY ASSESSMENT (150-200 words)

Provide:
- **Scientific Merit Score:** X/10 (with justification)
- **Fit for NPP Score:** X/10 (with justification)
- **Overall Recommendation:** Accept / Minor Revisions / Major Revisions / Reject
- **One-sentence rationale** for recommendation

### 2. MAJOR STRENGTHS (5 points, detailed)

For each strength:
- State the strength clearly
- Provide specific evidence from manuscript
- Explain why this is important for NPP
- Contextualize against NPP 2025 standards

Examples of potential strengths:
- Rigorous preprocessing methodology
- Drug-naïve sample eliminates confounds
- Clinically important research question
- Convergent evidence with independent work
- Novel sensorimotor circuit hypothesis

### 3. MAJOR CONCERNS (5 points, critical)

For each concern:
- State the issue clearly
- Explain impact on scientific validity or interpretation
- Assess severity (minor/moderate/critical)
- Provide specific recommendation for addressing

Examples of potential concerns:
- Absence of external validation
- Sample size below NPP 2025 standards
- Overfitting risk with high AUC on small N
- No comparison to clinical predictors
- Cross-sectional design limits mechanistic claims
- Generalizability limitations not adequately discussed

### 4. METHODOLOGICAL EVALUATION

Assess:
- **Preprocessing:** CONN toolbox, motion control, nuisance regression
- **Statistical approach:** Appropriate for sample size? Adequate corrections?
- **Sample characteristics:** Drug-naïve status, matching, homogeneity
- **Validation status:** Internal? External? None?
- **Reporting completeness:** Can others replicate this work?

### 5. SCIENTIFIC CONTRIBUTION ASSESSMENT

Evaluate:
- **Novelty:** What is new here compared to existing literature?
- **Significance:** Does this advance understanding or clinical practice?
- **Rigor:** Is evidence strong enough to support conclusions?
- **Impact potential:** Will this influence future research or clinical care?

### 6. TIER COMPLIANCE ANALYSIS

Report:
- **Tier 1 (Mandatory):** X/5 criteria met (list any failures)
- **Tier 2 (Standard):** X/8 criteria met (identify gaps)
- **Tier 3 (Excellence):** X/7 markers present

**Interpretation:** Use tier compliance to guide recommendation decision.

### 7. SPECIFIC RECOMMENDATIONS

Organize as:

**ESSENTIAL (must address for acceptance):**
- [ ] Recommendation 1 with specific action
- [ ] Recommendation 2 with specific action
- [ ] ...

**STRONGLY RECOMMENDED (should address for strong paper):**
- [ ] Recommendation 1 with specific action
- [ ] Recommendation 2 with specific action
- [ ] ...

**OPTIONAL ENHANCEMENTS (would strengthen paper):**
- [ ] Recommendation 1 with specific action
- [ ] Recommendation 2 with specific action
- [ ] ...

Examples:
- ESSENTIAL: Add internal cross-validation analysis (leave-one-out or k-fold)
- ESSENTIAL: Reframe claims as "exploratory candidate biomarker" not "validated biomarker"
- ESSENTIAL: Compare predictive accuracy to clinical variables alone
- STRONGLY RECOMMENDED: Expand limitations section to address generalizability concerns
- STRONGLY RECOMMENDED: Add sensitivity analysis with different response cutoffs (25%, 50%)
- OPTIONAL: Provide code/data sharing statement for reproducibility

### 8. DECISION RATIONALE

Provide:
- **Evidence-based justification** for your recommendation
- **Path forward for authors** (what must they do for acceptance?)
- **NPP 2025 standards alignment** (where does paper meet/fall short?)
- **Alternative scenarios** (e.g., "Would recommend acceptance if external validation added")
- **Resubmission potential** (if rejection recommended, is revision feasible?)

### 9. DECISION FRAMEWORK APPLIED

Use this logic:

**ACCEPT WITH MINOR REVISIONS if:**
- All Tier 1 mandatory criteria met
- ≥75% of Tier 2 standard expectations met
- Concerns addressable through text revisions only (no new analyses)
- Strong convergent evidence from independent work
- Clinical importance outweighs methodological limitations

**MAJOR REVISIONS if:**
- All Tier 1 mandatory criteria met
- 50-75% of Tier 2 standard expectations met
- Requires new analyses (cross-validation, clinical comparisons, robustness checks)
- Need repositioning of claims (exploratory → definitive)
- Substantial text revisions needed
- High resubmission potential after addressing concerns

**REJECT (with resubmission encouragement) if:**
- All Tier 1 mandatory criteria met
- <50% of Tier 2 standard expectations met
- Requires new data collection (external validation, larger sample)
- Fundamental limitations cannot be addressed without new study
- BUT: Study has merit and should be resubmitted after validation

**REJECT (terminal) if:**
- Any Tier 1 mandatory criterion failed
- Fatal methodological flaws
- Data integrity concerns
- Insufficient novelty for NPP
- Overfitting concerns cannot be addressed

---

## QUALITY STANDARDS FOR YOUR REVIEW

Your peer review should demonstrate:

1. **Evidence-based reasoning:** Cite specific manuscript sections, reference NPP 2025 standards
2. **Constructive tone:** Help authors improve, not just criticize
3. **Specificity:** Concrete recommendations, not vague suggestions
4. **Balance:** Acknowledge both strengths and limitations fairly
5. **Expertise:** Show deep knowledge of neuroimaging, OCD, statistics
6. **Professional standards:** Write at level expected for NPP peer review

**Avoid:**
- Simply summarizing the manuscript
- Being overly harsh or lenient without justification
- Making unsupported claims
- Ignoring context (exploratory vs definitive study design)
- Vague recommendations ("improve the methods" → specify HOW)

---

## SPECIAL CONSIDERATIONS

### Exploratory vs Definitive Framing

This study has:
- N=54 (exploratory range)
- No external validation
- Single-site design

**Question:** Should this be framed as:
- **Exploratory discovery** (hypothesis-generating, requires validation)
- **Definitive biomarker** (ready for clinical translation)

Most likely appropriate framing: **Exploratory candidate biomarker requiring validation**

Evaluate whether authors overstate conclusions given exploratory design.

### Clinical Pragmatism

Even with limitations, this study addresses:
- Important clinical problem (50% SSRI non-response)
- Feasible implementation (8-min rs-fMRI)
- Novel circuit hypothesis (sensorimotor vs canonical OCD circuits)
- Convergent evidence (Wang et al. 2025)

**Question:** Do clinical importance and methodological rigor outweigh validation limitations?

### Field Context

OCD treatment prediction literature:
- Small samples common (N=50-100 typical)
- External validation rare (but increasingly expected)
- Multiple circuits implicated (CSTC, DAN-FPN, sensorimotor)
- Clinical translation still aspirational

**Question:** Does this paper advance the field incrementally or substantially?

---

## FINAL INSTRUCTIONS

1. **Read the manuscript thoroughly:** `/Users/jiookcha/Documents/git/AI-CoScientist/input/37480_0_merged_1758766294.pdf`

2. **Apply NPP 2025 calibration standards** documented above

3. **Complete all 9 output sections** with specific, evidence-based content

4. **Use the three-tier framework** to guide your evaluation

5. **Provide actionable recommendations** that authors can implement

6. **Be constructive and professional** in tone

7. **Make a clear recommendation** with strong justification

---

## MULTI-AGENT REVIEW PROCESS

If using multiple AI models (GPT-4, Claude, Nemotron):

**Phase 1 - Independent Evaluation:**
- Each model reviews independently using this prompt
- No communication between models during initial review

**Phase 2 - Synthesis:**
- Compare evaluations across models
- Identify consensus areas (all models agree)
- Identify divergence areas (models disagree)
- Resolve conflicts through evidence-based discussion

**Phase 3 - Final Review:**
- Integrate strengths from each model's review
- Produce single comprehensive peer review
- Ensure internal consistency and professional quality

---

**Calibration Document Reference:** `/Users/jiookcha/Documents/git/Reviews/data/2025-10-npp/NPP_REVIEW_CALIBRATION_STANDARDS.md`

**Review Date:** October 26, 2025

**Target Journal:** Neuropsychopharmacology (NPP)

**Manuscript:** MS 37480 - Sensorimotor circuit connectivity as SSRI response biomarker in OCD

---

## BEGIN YOUR PEER REVIEW NOW

Using all the context, standards, and framework provided above, conduct a rigorous, professional peer review of manuscript MS 37480.
